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Abstract Chronic migraine (CM) is
an invalidating condition affecting a
significant population of headache
sufferers, frequently associated with
medication overuse headache
(MOH). Controlled trials and guide-
lines for the treatment of MOH are
currently not available. We studied
the efficacy of a therapeutic regimen
for the withdrawal of the overused
drug and detoxification in a sample
of patients suffering from probable
CM and probable MOH during
admission in eight hospitals of
Piemonte-Liguria-Valle d’Aosta.
Fifty patients, 42 females (84%) and
8 males (16%), mean age at observa-
tion 50.66±13.08 years, affected by
probable CM and daily medication
overuse following IHS diagnostic
criteria were treated as inpatients or
in a day hospital. Headache index
(HI) and daily drug intake (DDI)
were used for evaluating the severity
of headache and medication overuse.
The patients were treated by abrupt
discontinuation of the overused drug
and by a therapeutic protocol includ-
ing i.v. hydration, dexamethasone,
metoclopramide and benzodiazepines
for 7–10 days. Prophylactic medica-
tion was started immediately after
admission. Analgesics or triptans
were used under medical control
only in cases of severe rebound
headache. Diagnostic protocol
included routine blood tests (at
admission and at discharge), dosage
of B12 and folic acid. Patients
underwent follow-up controls one,
three and six months after discharge.
The initial diagnosis was probable
CM in almost all patients included in
the study (41 patients); in nine
patients the diagnosis was not speci-
fied (coded only as CDH). The
overused medications were simple
analgesics in 17 cases (34%), combi-
nation analgesics in 19 cases (38%),
triptans alone or with analgesics in
13 cases (26%) and ergotamine in 2
cases (4%). We collected data from
39 patients at first follow-up (1
month), 32 after 3 months and 14
after 6 months. Mean HI was 0.91 at
admission, 0.22 at discharge, 0.38
after 30 days, 0.46 after 3 months
and 0.48 after 6 months. Mean DDI
was 2.80 at admission, 0.39 at dis-
charge, 0.41 after 1 month, 0.52 after
3 months and 0.59 after 6 months.
These results are on average positive
and tend to remain stable with time.
Although preliminary and obtained
on a limited number of patients at 6-
month follow-up, our results seem to
be encouraging about the use of the
proposed therapeutic protocol. 
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Introduction
Chronic daily headache (CDH) is one of the main thera-
peutic problems within primary headaches. Chronic
migraine (CM) (following ICHD-II: 1.5.1 [1]), is one of
the most frequent causes of CDH.
Chronic abuse of ergotamine [2], analgesics [3], opi-
oids [4] and triptans [2–5] may lead to medication-
overuse headache (MOH), a secondary headache fre-
quently associated with CDH. Abrupt withdrawal of ergo-
tamine, analgesics and triptans [6] can also cause rebound
headache. The treatment of CDH and MOH includes the
withdrawal of the abused drug [7]. Further, some thera-
peutic protocols were proposed [8, 9] but controlled trials
and guidelines are currently not available. Hospitalisation
is recommended by several authors [10], but without gen-
eral consent [11].
We studied the efficacy of a withdrawal and detoxifi-
cation therapeutic regimen in 50 patients suffering from
probable CM and probable MOH, performed within eight
hospital headache centres. This protocol was followed by
a six-month follow-up.
Materials and methods
Fifty patients, 42 females (84%) and eight males (16%), mean age
at observation 50.66±13.08 years (range 24–76), affected by prob-
able CM (ICHD-II 1.6.5) and probable MOH (ICHD-II 8.2.7)
underwent a withdrawal and detoxification therapeutic regimen as
inpatients (25, 50%) or in a day hospital (25, 50%).
Inclusion criteria were: 
1. age ≥18 years;
2. diagnosis of CDH;
3. headache index (HI) ≥0.7;
4. daily drug intake (DDI) ≥1;
5. the above conditions having lasted for at least 6 months;
6. verbal informed consent.
The patients were enrolled after a clinical neurological evalua-
tion by an experienced headache specialist including diagnosis and
time patterns of primary headache, comorbidity, abused drug, pre-
vious prophylaxes and neurological examination. HI and DDI were
used for evaluating the severity of headache and medication
overuse within a one-month run-in period (T0). These data were
collected mostly as anamnestic data; some of the patients filled out
a headache diary. Clinical characteristics of the population are
shown in Table 1.
At admission (as inpatients or in a day hospital, according to
severity of the headache, amount and type of abused drug, and
preference of the patient), they underwent a diagnostic protocol
including blood tests (at admission and at discharge), dosage of
B12 and folic acid.
The treatment included:
1. Immediate withdrawal of all abused drugs;
2. i.v. hydration (1000–1500 cc of saline solution);
3. i.v. anxiolytic therapy (i.e., clordemetildiazepam 1–3 mg daily
or diazepam 5–15 mg daily);
4. i.v. dexamethasone (8 mg daily);
5. i.v. metoclopramide (10 mg daily).
In case of severe headache attacks, only single drugs were
allowed (triptans, 1 cp. daily; or lysine acetylsalicylate, 1000 mg
daily), and always different from the abused drug. Eight patients
(16%) took butalbital-containing preparations (mean daily dose
306.25 mg), but none of them presented symptoms of dependence
with need of phenobarbital therapy. Duration of treatment could
vary from nine to fifteen days. Prophylaxis was continued if pre-
sent at the beginning of treatment; if not, it was immediately start-
ed. All patients were instructed about the positive effects of behav-
ioural modifications. Follow-up data were collected by means of a
headache diary.
Patients were evaluated before (T0) and after (T10) our thera-
peutic regimen. They underwent follow-up controls one (T30),
three (T90) and six months (T120) after discharge. Due to the lim-
ited number of patients seen at the six-month follow-up visit, we
restricted the evaluation of results to the 32 patients seen at the
three-month follow-up visit. Statistical evaluation was performed
on HI and DDI using Student’s t-test vs. T0 data.
Results
The initial diagnosis was probable chronic migraine (1.6.5)
in 41/50 patients; in 9 patients the diagnosis was only
coded as CDH. The overused medications were simple
analgesics/NSAIDs in 14 cases (28%), analgesics/NSAIDs
in combination in 22 cases (44%), triptans alone in 6 cases
Table 1 Patients’ characteristics at observation. Data are expressed as mean±SD (range) except otherwise indicated
In-patients Day hospital Total
Males, n 3 5 8
Females, n 22 20 42
Mean age at observation, years 49.12±12.85 (24–74) 52.20±13.39 (29–76) 50.66±13.08 (24–76)
Length of overuse, years 4.41±8.10 (6 m–30 y) 1.80±3.53 (6 m–15 y) 3.41±6.27 (6 m–30 y)
Headache index 0.94±0.11 (0.7–1) 0.89±0.14 (0.7–1) 0.91±0.13 (0.7–1)
Daily drug intake 3.12±2.07 (1–10) 2.48±1.39 (1–6) 2.80±1.77 (1–10)
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(12%) or in association with analgesics/NSAIDs in 6 cases
(12%) and ergot derivatives (in combination) in 2 cases
(4%). Nineteen (38%) of our patients took more than one
preparation. Twenty-three patients (46%) took caffeine-
containing preparations (mean daily dose 270 mg). None
of our patients took opioid-containing preparations.
Comorbidity included anxious depression in 24
patients (48%), arterial hypertension in 8 patients (16%)
and obesity in 3 patients (6%). Only in one case gastric
disorders were reported.
Previous prophylactic treatments were: tricyclic anti-
depressants in 18 cases; calcium antagonists in 15 cases;
beta-blockers in 12 cases; SSRI in 8 cases; antiepileptic
agents in 8 cases; pizotifen in 4 cases; other pharmaco-
logical prophylaxes in 5 cases; and non-pharmacological
treatments in 2 cases (in 20 cases multiple prophylactic
treatments were reported). Seventeen patients did not take
any prophylaxis.
We found altered values of blood tests at the first visit
only in a minority of patients: high cholesterol levels in 7
cases, alteration of hepatic enzymes in 2 cases, low folate
values in 2 cases and mild hyperglycaemia in 1 case.
Three patients were early drop-outs and six were lost at
follow-up. Preliminary data were collected from 39 patients
after 1 month, 32 after 3 months and 14 after 6 months.
The suggested prophylaxis was: sodium valproate in
27 cases, amitriptyline in 6 cases, flunarizine in 6 cases,
propranolol in 6 cases, SSRI in 5 cases, topiramate in 5
cases and other prophylaxes in 2 cases. In some cases we
suggested a combined prophylaxis.
The time course of HI and DDI are shown in Figure 1.
Statistical evaluation of preliminary data is shown in
Table 2. However, data from these 32 patients do not sub-
stantially differ from those regarding all patients.
At the T30 visit, following the course of headache and
medication overuse, we were able to modify the original
diagnosis only in 26/32 patients, who withdrew drug
overuse. In 23 of them headache significantly improved,
allowing a diagnosis of MOH. The diagnosis was refined
following the revision of criteria for 8.2 Medication
overuse headache [12], so 4 were diagnosed as triptan-
overuse headache (8.2.2), 3 as Analgesic-overuse
headache (8.2.3), 9 as Combination analgesic-overuse
headache (8.2.5), and 7 as Medication-overuse headache
attributed to combination of acute medications (8.2.6).
Three patients reported persistence of frequent migrainous
attacks despite prophylaxis and so received a definite
diagnosis of CM (ICHD-II 1.5.1). Six out of 32 patients
continued medication overuse; their diagnosis remained
probable CM and probable MOH.
At T90, 19/32 patients (59.4%) experienced a signifi-
cant relief from headache (below one half of the initial
frequency), 24/32 (75.0%) significantly reduced drug
intake, and 8 (25.0%) were therapeutic failures.
Discussion
Although only preliminary, our data are in accordance
with previous observations [13] and are encouraging for
the use of the protocol. The differences in HI and DDI
before and after treatment are highly significant. These
results tend to remain stable with time. We obtained also
a good rate of positive individual results (59.4% for
headache relief and 75.0% for lowering drug intake).
It is difficult, due to the limited number of patients, to
draw conclusions from these data. We found only a corre-
lation between duration of overuse and unsuccessful out-
come (patients with a successful outcome had overused
medications for 1.71±2.27 years; those with unsuccessful
outcome had overused for 7±10.65 years: p<0.05). No
correlation between type and amount of overused drug
and successful outcome was found.Fig. 1 Time course of HI and DDI
Table 2 Statistical evaluation (Student’s t-test) on 32 patients at T0, T10, T30, T90
HI p vs. T0 DDI p vs. T0
T0 0.94±0.11 3.03±1.96
T10 0.21±0.27 <0.0001 0.36±0.65 <0.0001
T30 0.38±0.34 <0.0001 0.40±0.58 <0.0001
T90 0.46±0.36 <0.0001 0.52±0.60 <0.0001
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The critical period for a good outcome in these
patients is the first six months after detoxification.
We will continue the observation in the long-term fol-
lowing the promising results observed.
Acknowledgements We thank the following colleagues, mem-
bers of the Neurological Hospital Interregional Group for the
Study of Headache, who participated in the study with the
application of the protocol and follow-up observations: E.
Grasso (Cuneo); M. Maggio (Ivrea); D. Ferrandi
(Alessandria); E. Bottacchi, C. Lia (Aosta); E. Barbero
(Biella); M. Fonzari, D. Farinini, D. Santoloci (Genova, S.
Martino Hospital); F. Valguarnera (Genova, Sestri Ponente
Hospital); M. Gionco, A. Febbraro (Torino); G. Perego (Pietra
Ligure).
References
1. Headache Classification Subcommittee
of the International Headache Society
(2004) The International Classification
of Headache Disorders, 2nd edn.
Cephalalgia 24[Suppl 1]:1–160
2. Evers S, Gralow I, Bauer B et al
(1999) Sumatriptan and ergotamine
overuse and drug induced headache: a
clinicoepidemiologic study. Clin
Neuropharmacol 22:201–206
3. Granella F, Farina S, Malferrari G,
Manzoni GC (1987) Drug abuse in
chronic headache: a clinico-epidemio-
logic study. Cephalalgia 7:15–19
4. De Marinis M, Janiri L, Agnoli A
(1991) Headache in the use and with-
drawal of opiates and other associated
substances of abuse. Headache
31:159–163
5. Limmroth V, Katsarava Z, Fritsche G,
Diener HC (1999) Headache after fre-
quent use of new 5-HT agonists
zolmitriptan and naratriptan. Lancet
353:378–382
6. Katsarava Z, Fritsche G, Muessig M et
al (2001) Clinical features of with-
drawal headache following overuse of
triptans and other headache drugs.
Neurology 57:1694–1698
7. Hering R, Steiner TJ (1991) Abrupt
outpatients withdrawal of medication
in analgesic-abusing migraineurs.
Lancet 337:1442–1443
8. Pini LA, Bigarelli M, Vitale G,
Sternieri E (1996) Headaches associat-
ed with chronic use of analgesics: a
therapeutic approach. Headache
36:433–439
9. Bonuccelli U, Nuti A, Lucetti C et al
(1996) Amitriptyline and dexametha-
sone combined treatment in drug-
induced headache. Cephalalgia
16:197–200
10. Zed PJ, Loewen PS, Robinson G
(1999) Medication-induced headache:
overview and systematic review of
therapeutic approaches. Ann
Pharmacother 33:61–72
11. Suhr B, Evers S, Bauer B et al (1999)
Drug-induced headache: long-term
results of stationary versus ambulatory
withdrawal therapy. Cephalalgia
19:44–49
12. Silberstein SD, Olesen J, Bousser M-G
et al (2005) The International
Classification of Headache Disorders,
2nd edn. (ICHD-II) – revision of crite-
ria for 8.2 Medication-overuse
headache. Cephalalgia 25:460–465
13. Baumgartner C, Wessely P, Bingöl C et
al (1989) Longterm prognosis of anal-
gesic withdrawal in patients with drug-
induced headache. Headache
29:510–514
